Mark Eccleston Email & Phone Number

Nuneaton, England, Gb

Nuneaton, England, Gb

As part of the Commercial Advisory Board I help with strategic planning for ValiRx and its group companies, including the recent establishment of Inaphaea. ValiRx’s translational Contract Research Organisation. Recent activities include developing a plan for commercialisation of Inaphaea’s extensive biobank of Patient Derived Cells. These cells are a valuable resource, covering all major cancer indications and are a key part of Inaphaea’s service offering.

Nuneaton, England, Gb

As a member of ValiRx’s scientific Advisory Board I help to review potential early stage therapeutic assets for evaluation and jn licensing. Once brought into the company I also help with planning, experimental design and evaluation of those preclinical assets.

Nuneaton, England, Gb

Working with ValiRx to assess new preclinical assets for in-licensing and development. Great opportunity to review both small molecule and biological assets. We will leverage ValiRx’s wholly owned translational Clinical Research Organisation, Inaphaea ltd. and its biobank of nearly 500 Patient Derived Cells (PDCs) for the preclinical development phase of the in house programs. Also working to support Inaohaea’s commercialisation of its preclinical services and PDC biobank.

Henderson, Nevada, Us

As a member of Volition's Scientific Scientific Advisory board I will be supporting ongoing technical and scientific programs and providing sector relevant insight, competitive positioning and strategic guidance of how best to position Volition's various technology platforms across human and veterinary applications.It's a great opportunity to work with the internationally renowned board members and to help guide Volition as they commercialise their assays, develop novel approaches and progress clinical diagnostic trials.https://volition.com/team/mark-eccleston

Henderson, Nevada, Us

Providing expert knowledge to support the commercial roll out of Volition's Nu.Q® Discover commercialisation. Working with the business development team to support commercial positioning and build proposals for a range of Pharma, biotech and academic clients looking to exploit state of the art profiling of cell free circulating nucleosomes as PD biomarkers, measures of tumour burden, treatment response, minimal residual disease, toxicity monitoring and surrogate end points through the preclinical and clinical drug development pathway.https://volition.com/nu-q-discover

Henderson, Nevada, Us

Cofounder and named inventor on 27 patents for Volition ranging from novel biomarkers, novel platforms and novel therapeutic applications based on nucleosomes.A key part of this role includes identifying new and innovative infrastructures which will aid in the deployment of Volition's proprietary Nu.Q™ platform. Lightdeck is a great example and building the relationship with the team at Lightdeck lead directly to a $25M licensing deal with Heska for Volition’s Nu.Q Cancer Screen and Monitor test which will be deployed in the point of care platform.Responsible for strategic planning to ensure Volition's technology requirements are aligned to its short term needs whilst maintaining relevance for near and long term future commercial requirements.Horizon scanning, Identification, review and prioritisation of new and innovative technology infrastructures of relevance to volition and its commercial objectives.Development of policies and procedures for the deployment of technologies to enhance volitions products and services services.Review and prioritisation of Volitions technical programs in order to best achieve its commercial objectives based on cost-benefit and return on investment analyses.

Henderson, Nevada, Us

HyperGenomics is a genome wide epigenetic profiling technology based on mapping restriction nuclease sensitive regions of chromatin. The technology has many pharmaco- epigenomic applications, for example in patient stratification for clinical trials, companion diagnostic development and precision medicine as well as screening applications for epigenetic mutaions. HyperGenomics is a wholly owned Volition company.

Henderson, Nevada, Us

Development of a market entry plan for Volition's revolutionary Nucleosomics® blood testing technology.Recent successes include negotiation of an exclusive distribution agreement for Volition’s Research Use Only Nu.Q(TM) immunoassay with Active Motif as well as multiple equipment platform collaborations to exploit the Nucleosomics(TM) technology.Market planning and commercialisation of Volition's Nu.Q(TM) tests beginning with Colorectal cancer.This commercial role requires a great deal of technical knowledge and coordination between Volition’s expanding R&D team and external partners and leverages a deep scientific understanding of both Volition’s underlying technology and wider application areas.Successfully applied for two Eurostars grants. The most recent was for funding to develop a lung triage test based on Volition's Nu.Q immunoassays and Gyros Protein Technologies' GyroLab platform. Previous funding was for exemplification for a novel Graft vs Host disease profile and apply in Kidney transplant rejection. Mark is a co-inventor on many of the Volition patents and co author on several paper relating to the Nucleosomics technology immunoassay and the Nu.Q Capture technology . He is also a co inventor on Volition’s HyperGenomics (DNA Hypersensitive site profiling) patent

Henderson, Nevada, Us

• Establishing academic and clinical partnerships• Management commercial antibody development programs • Management of collaborations with serum banks

Ely, Uk, Gb

OncoLytika is a technology innovation company with internal development programmes in drug development, drug delivery and in-vivo imaging. We also develop products and services through consultancy mainly in the biotech sector but with interests in the renewable energy sector. OncoLytika is a partner of two current Innovate UK grants, contributing market assessment, exploitation planning and technical input on specialist Bio therapeutics and diagnostic antibody formulation. The two projects, AtlasBio and FastLyo focus on novel analytical tools for Freeze Drying optimisation. OncoLytika also project manages the two projects which follow on from a previous successful grant - BioStart.The teams involve a diverse range of academic and industry partners.Previous projects include commercial advisory and business planning roles for the University of Greenwich focussed on the spin out of a novel attenuated bacterial toxin DNA delivery system.OncoLytika has been successful in previous grant funding through the Eureka Eurostar programme. We conceptualised, wrote and project managed Volition’s successful GvHD/Organ Transplant rejection application in 2013 and we’re subcontracted to manage ValiRx’s first Eurostar GeneIce grant in 2008.OncoLytika is leveraging its business planning and R&D experience together with its network of contacts in preclinical development to provide a range of consultancy packages to the Pharma and Biotech industryServices include:-Opportunity recognistionDue DilligenceMarket AsessmentBuisiness PlannningProject Management

Co-founder and former Chief Scientific Officer of Vivamer Ltd. The Cambridge University soon out used responsive biopolymer chemistry to design novel intracellular delivery systems for drugs and imaging agents. Its scientific founders have an international reputation in the field of responsive polymers and are based at the Department of Chemical Engineering, University of Cambridge. The Intellectual Property (IP) has been developed with the support of £1.5m of research grants and seed funding from the University of Cambridge Challenge Fund, and is now being actively validated through collaborations with biopharmaceutical partners.Collaboration agreement signed with ValiRx to evaluate Vivamer delivery technology with GeneIce eligenetic gene silence technology.

Extensive networking and establishment of collaborations for ValiRx PlcInvolved in the tech. Transfer of the Nucleosomics® and HyperGenomics® platforms to Volition.Successfully applied for Eurostar funding for the GeneIce Programme (4th highest rated application in EU) which led to a second successful application for further preclinical development.

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics within its two divisions, ValiPharma and ValiBio. ValiPharma is using its unique GeneICE technology to develop therapeutics for more effective treatment of diseases such as cancer. The GeneICE platform enables selective gene silencing by targeted histone deacetylation leading to chromatin condensation.Mark was responsible for the preclinical development of a second therapeutic platform, a Src kinase inhibitor, which went on to successfully enter phase 1 clinical trials for the treatment of Androgen Resistant Prostate cancer.Mark is an inventor on further patents extending the applications of this family of inhibitors.ValiBio is developing diagnostics (and prognostic). Two technologies are under development. NucleosomicsTM is a platform for non-invasive (blood) tests for early cancer diagnosis based on epigenetic signal changes associated with malignancy. HyperGenomicsTM is an epigenetic platform for differential prognostic and diagnostic products for personalized cancer medicine. The basis of HyperGenomicsTM is to highly accurately identify tumours and tumour subtypes from the pattern of hypersensitive sites in the cells.These technologies were successfully sold to Volition which was formed to provide specific focus on the early detection capabilities in cancer.

development of a range of fluorescently labelled pH responsive polymers for in-vivo imaging appications

I am an enthusiastic, passionate and entrepreneurial scientist with a track record of over 12 years of applied research in the area of polymer chemistry with particular focus on synthesis, characterisation and applications of stimuli-responsive or ‘Smart’ polymers and biomedical applications.I have engaged with a number of applied and multidisciplinary research projects, funded by UK research councils and industrial sponsors and developed commercial applications in areas ranging from biomedical diagnostics to retail sportswear. The research output has been widely disseminated through peer-reviewed publications, conference presentations and patent filing. I have co-founded two companies and successfully secured research contracts valued in excess of £200,000. I am currently seeking to establish an independent career to enable me to develop a top quality research profile based on novel applications of responsive polymer technologies through academic research and spin off ventures.

I was one of the first BBSRC funded Enterprise fellows on the the scheme run with Scotish enterprise to provide formal business training for scientists. I was awarded an MBA (Entrepreneurship) through the Scheme following submission of a dissertation in 2007

Innovative applications of polymer chemistry in drug delivery, imaging and responsive hydrogels.

Founder and technical advisor to Cambridge Applied Polymers. CAP provided outsourced innovation and product development to Fast Moving Consumer Goods companies including several international companies.

designed a novel NIR fluorescent marker for monitoring distribution of fertilisers

Developed biodegradeable polymer systems for drug delivery

Birmingham City Centre, West Midlands, Gb

Mba, Business

Phd, Polymer Chemistry For Biomedical Applications

Bsc, Chemistry